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Abstract 
Background: Tubulin binding microtubule depolymerising agents form a growing group of tumor 
vascular disrupting agents (VDAs) in clinical trial, with combretastatin A-4-phosphate (CA4P) the lead 
compound. Signalling through RhoGTPase/ROCK-dependent pathways is central to CA4P-induced 
effects on endothelial cells in vitro (1). Here, we tested the hypothesis that RhoGTPase/ROCK 
signalling is also important in tumor vascular damaging effects in vivo.  
Experimental procedures: SW1222 human colorectal carcinoma cells were grown as solid sub-
cutaneous tumors in SCID mice. The Rho kinase (ROCK) inhibitor, Y-27632 (50 mg/kg) or saline 
vehicle, was administered intraperitoneally (i.p.), 5 minutes prior to 100 mg/kg CA4P or saline i.p. 
Laser Doppler flowmetry was used to assess tumor vascular response from 0 – 2h post-treatment, under 
isofluorane anaesthesia. Intravenous administration of fluorescent tomato lectin was used for assessing 
tumor perfusion at 1, 3, 6 and 24 hours post-CA4P/saline treatment, unanaesthetised. Necrosis (H&E) 
and leukocyte infiltration (immunohistochemistry) were assessed at 24h from excised tumors. Mean 
arterial blood pressure (MABP) was monitored in unanaesthetised mice without tumors, using a tail 
cuff system.  
Results: Y-27632 alone significantly decreased MABP by 40% but did not significantly affect tumor 
necrosis at 24 hours (17±4% of tumor sectional area for treated versus 10±3% for controls). Y-27632 
alone reduced relative red cell flux in the tumor (laser Doppler flowmetry) by approximately 50%, 
which was similar to the reduction observed for CA4P alone. However, pre-treatment with Y-27632 
did not affect CA4P-induced laser Doppler or perfused vascular volume measurements in the first few 
hours after CA4P and significantly reduced the effect of CA4P on perfused vascular volume and 
necrosis measured at 6 and 24 hours. Necrosis was 61±5% for CA4P alone and 35±7% for Y-
27632+CA4P. These changes were accompanied by a decrease in staining for the myeloid markers, 
myeloperoxidase and GR-1 with Y-27632 pre-treatment.  
Conclusions: The Y-27632-induced decrease in MABP is consistent with the decrease in relative red 
cell flux in the tumor, via a decrease in tumor perfusion pressure. Despite these effects of Y-27632 
alone, its administration prior to CA4P was protective of CA4P-induced vascular damage at the later 
time-points, suggesting that ROCK inhibition is acting downstream from initial vascular shut-down, 
potentially via modulation of myeloid cell recruitment. These data indicate that RhoGTPase/ROCK-
dependent signalling is a critical factor in determining extent of vascular disruption by CA4P – these 
results have significance for similar VDAs in development.  
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